# Pizarra — PT-pseudo_4edb17f79e46 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4edb17f79e46
Task: 1

Encounter: Urology - outpatient on 25 Feb 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.16 ng/mL²
  - PSA velocity: 1.51 ng/mL/yr
  - Prior PSA: 7.5 ng/mL
  - Prostate volume: 57.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7709042 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 57 mL. csPCa 0.77.

Vitals: weight 72 kg, height 177 cm, BMI 23.0, BP 161/76 mmHg, HR 73 bpm. Smoking: Non-smoker.

Chief complaint: A documented upward trajectory in prostate-specific antigen levels alongside a previously negative biopsy necessitates clinical re-assessment.

History: This 54-year-old gentleman works as a retired farmer residing in a ground-floor apartment shared with his partner. He originally entered the diagnostic pathway in May 2023 due to an elevated PSA. A non-smoker with no comorbidities or active medications, he maintains an active routine that includes running five kilometres three times weekly and consumes approximately thirteen units of alcohol each week. Lower urinary tract symptoms remain minimal, reflected by an IPSS score of five, and he explicitly denies haematuria, unexplained weight loss, or bone pain. His surgical past includes a childhood appendectomy and a right knee arthroscopy for a meniscal tear conducted fifteen years prior. Recent visits to an audiology clinic for standard hearing screening noted occasional mild tinnitus, though he otherwise reports feeling well. He commutes roughly sixty minutes by train to reach this facility. A prior biopsy returned negative, and digital rectal examination is normal.

Physical examination: On examination, digital rectal assessment is normal; the prostate reveals a symmetrically enlarged contour, smooth and firm consistency, with no palpable nodules or asymmetry. General inspection shows a blood pressure of 161/76 mmHg with a regular pulse of 73 beats per minute. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired farmer; Married; Lives in ground-floor apartment with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Running 3x/week, 5 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.75 +/- 0.17   (95% CI 0.36-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.14  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=9.2, age=54.0, psad=0.16, dre_ord=0.0, vol=57.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS 4, PSA 9.2, prior negative biopsy, PSA velocity 1.51 ng/mL/yr, csPCa probability 0.7709042) and could not account for the context provided by the retrieved documents, such as the specific PSA trajectory or the details of the mpMRI findings.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.75), but the guideline criterion is conditional on the specific MRI finding (PI-RADS 4-5 lesion) and the lack of change, which the prior did not explicitly weigh against the clinical context. The prior's uncertainty interval suggests the decision is highly sensitive to unobserved variables, such as the specific PSA velocity or the details of the MRI prose.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

GUIDELINE ANCHOR
The guideline states that a repeat biopsy after a negative biopsy should be considered dependent on risk factors (e.g., PSA density, PI-RADS score). It also notes that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, which may miss some cancers.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_4edb17f79e46", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 10 Feb 2025 | Reporting Unit: Antoni van Leeuwenhoek Imaging Department\n\nClinical Indication:\nA re-evaluation is required following an elevated PSA value of 9.2 ng/mL and a previously negative biopsy.\n\nFINDINGS:\nThe gland measures 57.0 mL in total volume. A discrete abnormality sits at the base-to-mid junction of the left peripheral zone, spanning roughly 12 mm. T2-weighted sequences show the mass as hypointense compared to adjacent tissue. Diffusion-weighted imaging highlights pronounced restricted diffusion, corroborated by low ADC signal. Post-contrast phases capture early, focal enhancement within the abnormality. Benign nodular hyperplasia characterizes the transition zone, lacking suspicious characteristics. There is no evidence of extraprostatic extension or seminal vesicle invasion, and pelvic lymph nodes appear normal.\n\nIMPRESSION:\nPI-RADS 4 lesion located in the left peripheral zone, approximately 12 mm. Prostate volume 57.0 mL, yielding a PSA density of 0.16 ng/mL/mL. csPCa predicted probability 0.7709042."}
get_psa_trend
{"case_id": "PT-pseudo_4edb17f79e46", "psa_trend": [{"date": "May 2023", "val": 8.4}, {"date": "Oct 2023", "val": 2.6}, {"date": "Apr 2024", "val": 3.4}, {"date": "Sep 2024", "val": 4.7}, {"date": "Feb 2025", "val": 9.2}]}
get_previous_notes
{"case_id": "PT-pseudo_4edb17f79e46", "previous_notes": [{"date": "04 Sep 2023", "author": "Dr. S. de Vries (GP)", "text": "Initial evaluation in May 2023 recorded a PSA level of 4.2 ng/mL. Subsequent testing in October revealed an upward trajectory to 6.0 ng/mL, which led to a urology referral for a thorough assessment. A transperineal biopsy was carried out and yielded negative results. The continuing upward trend in current PSA levels has prompted this follow-up consultation."}]}
get_lab_results
{"case_id": "PT-pseudo_4edb17f79e46", "laboratory_results": [{"name": "PSA", "val": "9.2 ng/mL", "date": "10 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.42 ng/mL", "date": "10 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "10 Feb 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "10 Feb 2025", "flag": ""}, {"name": "WBC", "val": "7.0 x10^9/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "159 x10^9/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "91 umol/L", "date": "10 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "10 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "16.4 nmol/L", "date": "10 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "59 U/L", "date": "10 Feb 2025", "flag": ""}, {"name": "LDH", "val": "172 U/L", "date": "10 Feb 2025", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion located in the left peripheral zone, approximately 12 mm.
- PSA trend: Rising trajectory from 8.4 ng/mL (May 2023) to 9.2 ng/mL (Feb 2025).
- Previous notes: Prior biopsy was negative, and the patient is undergoing re-evaluation due to upward PSA trajectory.

AGAINST sampling this patient now:
- MRI report: No evidence of extraprostatic extension or seminal vesicle invasion.
- MRI report: Lesion is described as PI-RADS 4, not 5.

WHERE THIS LEANS
The evidence strongly supports re-biopsy based on the PI-RADS 4 finding and the documented upward PSA trajectory following a negative biopsy. This leans toward the guideline criterion of re-biopsy for PI-RADS 4 lesions.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The guideline criterion strongly supports re-biopsy due to the PI-RADS 4 lesion, which is weighted as decisive. This decision is further supported by the documented upward PSA trajectory from 8.4 ng/mL to 9.2 ng/mL following a prior negative biopsy. The evidence converges on the need for further sampling to evaluate the suspicious lesion identified on the mpMRI.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
